TEVA - Teva Pharmaceutical Industries Limited
About Teva Pharmaceutical Industries Limited (https://www.tevapharm.com)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Richard Francis | President, Chief Executive Officer & Director | 1968 | $7,168,739 USD |
| Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer | 1974 | $3,162,002 USD |
| Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer | 1970 | $2,548,950 USD |
| Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise | 1969 | $2,495,184 USD |
| Evan Lippman | Executive Vice President of Business Development | 1970 | $2,322,034 USD |
| Matthew Shields | Executive Vice President of Global Operations | 1975 | $2,254,090 USD |
| Richard Gordon Daniell | Executive Vice President of European Commercial | 1967 | $2,133,302 USD |
| Mark Sabag | Executive Vice President of International Markets Commercial | 1971 | $1,729,144 USD |
| Advocate Nir Baron | Senior Vice President & Chief Internal Auditor | – | – |
| Amir Weiss | Senior Vice President & Chief Accounting Officer | 1977 | – |
| Brian Savage | Interim Chief Legal Officer | – | – |
| Christopher J. Stevo | Senior Vice President of Investor Relations & Competitive Intelligence | – | – |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer | – | – |
| Kevin C. Mannix | Senior Vice President of Investor Relations | – | – |
| Placid Jover | Executive Vice President & CHRO | 1982 | – |